Altered plasma fibrin clot properties in essential thrombocythemia

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Platelets

• Publication date

  2015-05-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/09537104.2015.1042967PMID 25989112
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union

  2014cited by this paper
• Selected parameters of hemostasis in patients with myeloproliferative neoplasms

  2014cited by this paper
• Phospholipid‐dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia

  2014cited by this paper
• Altered plasma fibrin clot properties and fibrinolysis in patients with multiple myeloma

  2014cited by this paper
• Fibrin clot properties and their modulation in thrombotic disorders

  2014cited by this paper
• Altered plasma fibrin clot properties in patients with digestive tract cancers: links with the increased thrombin generation.

  2013cited by this paper
• Venous thrombosis: who should be screened for thrombophilia in 2014?

  2013cited by this paper
• Current concepts of percutaneous balloon kyphoplasty for the treatment of osteoporotic vertebral compression fractures: evidence-based review.

  2013cited by this paper
• Plasma P-selectin Predicts Long-term Cardiovascular Events in Hospitalized Patients with Suspected Coronary Artery Disease and Preserved Left Ventricular Function: A 10-Year Follow-Up Study

  2013cited by this paper
• Altered fibrin clot properties are associated with residual vein obstruction: effects of lipoprotein(a) and apolipoprotein(a) isoform.

  2012cited by this paper
• Fibrin Clot Properties in Acute Stroke: What Differs Cerebral Hemorrhage From Cerebral Ischemia?

  2012cited by this paper
• Abnormal plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thromboangiitis obliterans.

  2011cited by this paper
• Platelets Retain High Levels of Active Plasminogen Activator Inhibitor 1

  2011cited by this paper
• Treatment related changes in antifibrinolytic activity in patients with polycythemia vera

  2010cited by this paper
• Fibrin clot properties in acute ischemic stroke: relation to neurological deficit.

  2010cited by this paper
• Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.

  2010cited by this paper
• JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.

  2009cited by this paper
• The influence of low-dose aspirin and hydroxyurea on platelet–leukocyte interactions in patients with essential thrombocythemia

  2009cited by this paper
• Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: Relationship with thrombosis occurrence and JAK2 V617F allele burden

  2009cited by this paper
• The 2008 World Health Organization classification system for myeloproliferative neoplasms

  2009influential reference
• Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives.

  2009cited by this paper
• Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress.

  2008cited by this paper
• Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with Essential Thrombocythemia

  2007cited by this paper
• Platelet Factor 4 (CXCL4) Seals Blood Clots by Altering the Structure of Fibrin*

  2007cited by this paper
• Polyphosphate enhances fibrin clot structure.

  2007cited by this paper
• Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status.

  2006cited by this paper
• Treatment of symptomatic patients with essential thrombocythemia: Effectiveness of anagrelide

  2005cited by this paper
• Role of P-selectin and PSGL-1 in coagulation and thrombosis

  2004cited by this paper
• Management of patients with essential thrombocythemia: current concepts and perspectives.

  2001cited by this paper
• The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia

  2001cited by this paper
• The Plasma Levels of Prostanoids and Plasminogen Activator Inhibitor-1 in Primary and Secondary Thrombocytosis

  2000cited by this paper
• Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.

  2000cited by this paper
• Reduced in vitro clot lysis and release of more active platelet PAI-1 in polycythemia vera and essential thrombocythemia.

  1998cited by this paper
• The use of aspirin in polycythaemia vera and primary thrombocythaemia.

  1998cited by this paper
• Contribution of platelets to PAI-1 concentration in plasma of patients with primary and secondary thrombocytosis

  1997cited by this paper
• Thrombotic complications in essential thrombocythemia with relatively low platelet counts

  1997cited by this paper
• Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.

  1995cited by this paper
• Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment.

  1995cited by this paper
• Fibrinolytic imbalance in essential thrombocythemia: role of platelets.

  1993cited by this paper
• Platelet factor 4 enhances fibrin fiber polymerization.

  1987cited by this paper
• Order out of chaos

  1984cited by this paper

• Calreticulin—From the Endoplasmic Reticulum to the Plasma Membrane—Adventures of a Wandering Protein

  2025cites this paper
• Prothrombotic profiles in myelofibrosis: Fibrinogen oxidation and the beneficial effects of ruxolitinib.

  2025cites this paper
• Fibrinogen Oxidation and Thrombosis: Shaping Structure and Function

  2025cites this paper
• Impaired fibrinolysis in JAK2V617F-related myeloproliferative neoplasms.

  2024cites this paper
• Proteomic screening identifies PF4/Cxcl4 as a critical driver of myelofibrosis

  2024cites this paper
• Fibrin Clot Properties in Cancer: Impact on Cancer-Associated Thrombosis

  2023cites this paper
• A portable, low cost clot permeability measurement system

  2023cites this paper
• Thrombosis and hemorrhage in myeloproliferative neoplasms: The platelet perspective

  2022cites this paper
• JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome

  2022cites this paper
• Therapy with high-dose statins reduces soluble P-selectin: The impact on plasma fibrin clot properties.

  2022cites this paper
• In‐Hospital Outcomes of Acute Myocardial Infarction With Essential Thrombocythemia and Polycythemia Vera: Insights From the National Inpatient Sample

  2022cites this paper
• Treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened Kidney Function

  2021cites this paper
• Glanzmann thrombasthenia complicated by frequent myeloproliferative neoplasm‐related thromboembolism: thrombosis occurring regardless of αIIbβIII integrin deficiency

  2021cites this paper
• Heparin‐induced thrombocytopenia leading to a diagnosis of essential thrombocythemia

  2021cites this paper
• Essential thrombocythemia: a hemostatic view of thrombogenic risk factors and prognosis

  2020cites this paper
• Complex intracranial vascular complications caused by essential thrombocythemia: a critical case report

  2020cites this paper
• Plasma fibrin clot proteomics in healthy subjects: Relation to clot permeability and lysis time.

  2019cites this paper
• Prothrombotic fibrin clot properties associated with increased endogenous thrombin potential and soluble P‐selectin predict occult cancer after unprovoked venous thromboembolism

  2019cites this paper
• Peripheral circulatory disorders in essential thrombocythemia.

  2018cites this paper
• Erythrocyte compression index is impaired in patients with residual vein obstruction

  2018cites this paper
• Fibrin Formation, Structure and Properties.

  2017cites this paper
• How to Assess Fibrinogen Levels and Fibrin Clot Properties in Clinical Practice?

  2016cites this paper